Study Phase 3

A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedAnxiety Disorders
Sponsor Protocol NumberRIS-ANX-301Enrollment417Data PartnerJohnson & Johnson% Female90.0%Mean/Median Age (Years)44.2% White70.8%

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.